Health Care [ 2/12 ] | Biotechnology [ 3/73 ]
NASDAQ | Common Stock
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer.
The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity.
Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2.
Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
As of August 28, 2025, iTeos Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 25 | -1.28 Decreased by -611.11% | -0.89 Decreased by -44.11% |
| May 8, 25 | -0.80 Increased by +25.23% | -0.90 Increased by +11.46% |
| Mar 4, 25 | -1.03 Decreased by -21.18% | -1.02 Decreased by -0.82% |
| Nov 5, 24 | -1.05 Decreased by -16.83% | -0.89 Decreased by -18.15% |
| Aug 8, 24 | -0.18 Increased by +81.25% | -1.04 Increased by +82.69% |
| May 10, 24 | -1.07 Decreased by -143.18% | -1.26 Increased by +15.08% |
| Mar 6, 24 | -0.85 Decreased by -251.79% | -1.03 Increased by +17.48% |
| Nov 7, 23 | -0.90 Decreased by -3.10 K% | -1.20 Increased by +25.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by -100.00% | -78.73 M Decreased by -1.00 K% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -34.61 M Increased by +9.43% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Increased by +100.00% | -43.71 M Decreased by -43.08% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -45.36 M Decreased by -40.68% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 35.00 M Increased by +N/A% | -7.13 M Increased by +79.22% | Decreased by -20.37% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -38.22 M Decreased by -145.75% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | -11.30 M Decreased by -120.97% | -30.55 M Decreased by -249.37% | Increased by +270.29% Increased by +612.37% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -32.24 M Decreased by -3.35 K% | Decreased by N/A% Decreased by N/A% |